Unicycive Therapeutics (NASDAQ:UNCY) fixed a third‑party manufacturing problem, resubmitted its FDA filing which was accepted with a June 29, 2026 action date, while brokers remain bullish—B. Riley keeps a $22 target and HC Wainwright trims its target to $15.
Previous Week Recap
- Unicycive FDA Filing Resubmission: Unicycive Therapeutics (UNCY) corrected a third‑party manufacturing issue, resubmitted its FDA filing in late 2025; FDA accepted it and set a target action date of June 29.
- Brokerages Hold/Adjust UNCY Targets: Two brokerages kept Buy ratings on Unicycive Therapeutics (UNCY); B. Riley left its $22 target, HC Wainwright cut its target to $15.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.